News | December 06, 2023
Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
GMM Pfaudler US completes acquisition of MixPro
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The Product will be manufactured at the company's facility in Bengaluru
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
This product will be manufactured at Lupin’s Pithampur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Subscribe To Our Newsletter & Stay Updated
